Treatment-related myelodysplastic syndrome after temozolomide use in a child: First report

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 11, 2008, Pages 857-859

  Dufour, Christelle ^a   Costa, Lydie Da ^a,b,c   Auger, Nathalie ^a   Jullien, Marc ^d   Bhangoo, Ranjeev ^a   Grill, Jacques ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d Troyes Hospital   (France)

Author keywords

Brain tumor; Child; Temozolomide; Treatment related myelodysplasia

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; HEMOGLOBIN; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE;

ANAMNESIS; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CHILD; CHROMOSOME ANALYSIS; CLINICAL FEATURE; DIFFUSE LEPTOMENINGEAL OLIGODENDROGLIOMATOSIS; DISEASE COURSE; ERYTHROID CELL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GLIOSIS; HUMAN; HUMAN TISSUE; KARYOTYPE 46,XY; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MEGAKARYOCYTE; MOLECULAR CLONING; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SCHOOL CHILD; SKULL IRRADIATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; BRAIN TUMOR; CHEMICALLY INDUCED DISORDER; FATALITY; GENETICS; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHILD; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DACARBAZINE; FATAL OUTCOME; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES;

EID: 58149147634     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318182e74f     Document Type: Article

References (17)

1. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000;6:2585-2597.
2. Jaeckle KA, Hess KR, Yung WK, et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2003;21:2305-2311.
3. Quinn JA, Desjardins A, Weingart J, et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005;23:7178-7187.
4. Yung WK. Temozolomide in malignant gliomas. Semin Oncol. 2000; 27:27-34.
5. Estlin EJ, Lashford L, Ablett S, et al. Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. Br J Cancer. 1998;78:652-661.
6. Lashford LS, Thiesse P, Jouvet A, et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol. 2002;20:4684-4691.
7. Noronha V, Berliner N, Ballen KK, et al. Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. Neuro Oncol. 2006;8:280-283.
8. Su YW, Chang MC, Chiang MF, et al. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neurooncol.2005;71:315-318.
9. Meadows AT, Obringer AC, Marrero O, et al. Second malignant neoplasms following childhood Hodgkin's disease: treatment and splenectomy as risk factors. Med Pediatr Oncol. 1989;17: 477-484.
10. Duffner PK, Krischer JP, Horowitz ME, et al. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol. 1998;44: 313-316.
11. Broniscer A, Ke W, Fuller CE, et al. Second neoplasms in pediatric patients with primary central nervous system tumors: the St. Jude Children's Research Hospital experience. Cancer.2004;100: 2246-2252.
12. Barnard DR, Woods WG. Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer - an update. Leuk Lymphoma. 2005;46:651-663.
13. Park DJ, Koeffler HP. Therapy-related myelodysplastic syndromes. Semin Hematol. 1996;33:256-273.
14. Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31:727-736.
15. Pershouse MA, El-Naggar AK, Hurr K, et al. Deletion mapping of chromosome 4 in head and neck squamous cell carcinoma. Oncogene. 1997;14:369-373.
16. Yamaguchi T, Toguchida J, Yamamuro T, et al. Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q, 17p, and 18q. Cancer Res. 1992;52:2419-2423.
17. Tschentscher F, Prescher G, Horsman DE, et al. Partial deletions of the long and short arm of chromosome 3 point to two tumor suppressor genes in uveal melanoma. Cancer Res. 2001;61:3439-3442.